Ann: CORE NK Platform Phase 1 Clinical Data Presentation, page-34

Rolling, you add no value. I respect and welcome a contrary opinion... if it has merit and adds value - yours does not.

This was a trial focuses primarily on blood cancers and we saw results in patients with SOLID TUMOURS - how is that not a win?

One patient who has had THREE prior treatments is now CANCER FREE - how is that not a win?

You say the company is over valued, yet it's showing promise in a market that only has FOUR approved drugs, all of which have one of the lowest bars for efficacy and survival. Not to mention the last drug approved in this space was 2011.